Genetic replacement of surfactant protein-C reduces respiratory syncytial virus induced lung injury

Respiratory Research

Thomas R Korfhagen³  Kristen Page³  John E Baatz²  Teah L Ruetschilling¹  Melissa D Maxfield³  Albert P Senft¹  Stephan W Glasser³ 

[1] Lovelace Respiratory Research Institute, Albuquerque, NM, USA;Medical University of South Carolina, Charleston, South Carolina, USA;Cincinnati Children’s Hospital Medical Center, Perinatal Institute, Division of Neonatology, Perinatal and Pulmonary Biology, MLC7029, 3333 Burnet Avenue, Cincinnati, OH, 45229-3039, USA

关键词: Clara cell secretory protein (CCSP);    Interstitial lung disease;    Lung inflammation;    Type II cells;    Respiratory syncytial virus;    Surfactant protein-C;   

Others  :  796530
DOI  :  10.1186/1465-9921-14-19

 received in 2012-10-18, accepted in 2013-02-08,  发布年份 2013

【 摘 要 】

Background

Individuals with deficiencies of pulmonary surfactant protein C (SP-C) develop interstitial lung disease (ILD) that is exacerbated by viral infections including respiratory syncytial virus (RSV). SP-C gene targeted mice (Sftpc -/-) lack SP-C, develop an ILD-like disease and are susceptible to infection with RSV.

Methods

In order to determine requirements for correction of RSV induced injury we have generated compound transgenic mice where SP-C expression can be induced on the Sftpc -/- background (SP-C/Sftpc -/-) by the administration of doxycycline (dox). The pattern of induced SP-C expression was determined by immunohistochemistry and processing by Western blot analysis. Tissue and cellular inflammation was measured following RSV infection and the RSV-induced cytokine response of isolated Sftpc +/+ and -/- type II cells determined.

Results

After 5 days of dox administration transgene SP-C mRNA expression was detected by RT-PCR in the lungs of two independent lines of bitransgenic SP-C/Sftpc -/- mice (lines 55.3 and 54.2). ProSP-C was expressed in the lung, and mature SP-C was detected by Western blot analysis of the lavage fluid from both lines of SP-C/Sftpc -/- mice. Induced SP-C expression was localized to alveolar type II cells by immunostaining with an antibody to proSP-C. Line 55.3 SP-C/Sftpc -/- mice were maintained on or off dox for 7 days and infected with 2.6x10⁷ RSV pfu. On day 3 post RSV infection total inflammatory cell counts were reduced in the lavage of dox treated 55.3 SP-C/Sftpc -/- mice (p = 0.004). The percentage of neutrophils was reduced (p = 0.05). The viral titers of lung homogenates from dox treated 55.3 SP-C/Sftpc -/- mice were decreased relative to 55.3 SP-C/Sftpc -/- mice without dox (p = 0.01). The cytokine response of Sftpc -/- type II cells to RSV was increased over that of Sftpc +/+ cells.

Conclusions

Transgenic restoration of SP-C reduced inflammation and improved viral clearance in the lungs of SP-C deficient mice. The loss of SP-C in alveolar type II cells compromises their response to infection. These findings show that the restoration of SP-C in Sftpc -/- mice in response to RSV infection is a useful model to determine parameters for therapeutic intervention.

【 授权许可】

   
2013 Glasser et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Glasser SW, Baatz JE, Korfhagen TR: Surfactant protein-C in the maintenance of lung integrity and function. J Aller Ther 2011, S7-001. in press
• [2]Thomas AQ, Lane K, Phillips J 3rd, Prince M, Markin C, Speer M, Schwartz DA, Gaddipati R, Marney A, Johnson J, Roberts R, Haines J, Stahlman M, Loyd JE: Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002, 165:1322-1328.
• [3]Gower WA, Nogee LM: Surfactant dysfunction. Paediatric Respir Rev 2011, 12:223-229.
• [4]Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA: A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001, 344:573-579.
• [5]Trendano M, Griese M, Brasch F, Schumacher S, de Blic J, Maraque S, Houdayer C, Elion J, Couderc R, Bahuau M: Mutation of SFTPC in infantile pulmonary alveolar proteinosis with or without fibrosising lung disease. Am J Med Genet 2004, 126A:8-26.
• [6]Wambach JA, Yang P, Wegner DJ, An P, Hackett BP: Surfactant protein-C promoter variants associated with neonatal respiratory distress syndrome reduce transcription. Ped Res 2010, 68:216-220.
• [7]Glasser SW, Burhans MS, Korfhagen TR, Na CL, Sly PD, Ross GF, Ikegami M, Whitsett JA: Altered stability of pulmonary surfactant in SP-C-deficient mice. Proc Natl Acad Sci USA 2001, 98:6366-6371.
• [8]Glasser SW, Detmer EA, Ikegami M, Na CL, Stahlman MT, Whitsett JA: Pneumonitis and emphysema in Sp-C gene targeted mice. J Biol Chem 2003, 278:14291-14298.
• [9]Bullard JE, Nogee LM: Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation. Ped Res 2007, 62:176-179.
• [10]Chibbar R, Shih F, Baga M, Torlakovic E, Ramlall K, Skomro R, Cockcroft DW, Lemire EG: Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. Mod Pathol 2004, 17:973-980.
• [11]Collins PL, Melero JA: Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011, 162:80-99.
• [12]Bem RA, Domachowske JB, Rosenberg HF: Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 2011, 301:L148-L156.
• [13]Parker D, Prince A: Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 2011, 45:189-201.
• [14]Glasser SW, Witt TL, Senft AP, Baatz JE, Folger D, Maxfield MD, Akinbi HT, Newton DA, Prows DR, Korfhagen TR: Surfactant protein C deficient mice are susceptible to respiratory syncytial virus infection. Am J Physiol Lung Cell Mol Physiol 2009, 297:L64-L72.
• [15]Tichelaar JW, Lu W, Whitsett JA: Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J Biol Chem 2000, 275:11858-11864.
• [16]Clark JC, Tichelaar JW, Wert SE, Itoh N, Perl AK, Stahlman MT, Whitsett JA: FGT-10 disrupts lung morphogenesis and causes pulmonary ademonas in vivo. Am J Physiol Lung Cell Mol Physiol 2001, 280:L705-L715.
• [17]Perl AK, Tichelaar JW, Whitsett JA: Conditional gene expression in the respiratory epithelium of the mouse. Transgenic Res 2002, 11:21-29.
• [18]Furth PA, St Onge L, Böger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L: Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A 1994, 91:9302-9306.
• [19]Rice WR, Conkright JJ, Na CL, Ikegami M, Shannon JM, Weaver TE: Maintenance of the mouse type II cell phenotype in vitro. Am J Physiol Lung Cell Mol Physiol 2002, 283:L256-L264.
• [20]Glasser SW, Maxfield MD, Ruetschilling TL, Akinbi HT, Baatz JE, Kitzmiller JA, Page K, Xu Y, Bao E, Korfhagen TR: Persistence of LPS induced lung inflammation in surfactant protein-C deficient mice. Am J Resp Cell Mol Biolsubmitted
• [21]Tian B, Zhang Y, Luxon BA, Garofalo RP, Casola A, Sinha M, Brasier AR: Identification of NF-kappaB-dependent gene networks in respiratory syncytial virus-infected cells. J Virol 2002, 76:6800-14.
• [22]Whitsett JA, Wert SE, Weaver TE: Alveolar surfactant homeostasis and pathogenesis of pulmonary disease. Ann Rev Med 2010, 61:105-119.
• [23]Mulugeta S, Beers MF: Surfactant protein C: its unique properties and emerging immunomodulatory role in the lung. Microbes Infect 2006, 8:2317-2323.
• [24]Martinez FD: Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J 2003, 22:S76-S82.
• [25]Bridges JP, Xu Y, Na CL, Wong HR, Weaver TE: Adaptation and increased susceptibility to infection associated with constitutive expression of misfolded SP-C. J Cell Biol 2006, 172:395-407.
• [26]Schreiber P, Matheise JP, Dessy F, Heimann M, Letesson JJ, Coppe P, Collard A: High mortality rate associated with bovine respiratory syncytial virus (BRSV) infection in Belgian white blue calves previously vaccinated with an inactivated BRSV vaccine. J Vet Med B Infect Dis Vet Public Health 2000, 47:535-550.
• [27]Whitsett JA, Perl AKT: Conditional control of gene expression in the respiratory epithelium. Am J Respir Cell Mol Biol 2006, 34:519-520.
• [28]LeVine AM, Elliott J, Whitsett JA, Srikiatkhachorn A, Crouch E, DeSilva N, Korfhagen TR: Surfactant protein-D enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. Am J Respir Cell Mol Biol 2004, 31:193-199.
• [29]LeVine AM, Gwozdz J, Stark J, Bruno M, Whitsett J, Korfhagen T: Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest 1999, 103:1015-10121.
• [30]Numata M, Chu HW, Dakhama A, Voelker DR: Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proc Natl Acad Sci U S A 2010, 107:320-325.
• [31]Nishino M, Mizuno D, Kimoto T, Shinahara W, Fukuta A, Takei T, Sumida K, Kitamura S, Shiota H, Kido H: Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs. Vaccine 2009, 27:5620-5627.
• [32]Mizuno D, Kimoto T, Takei T, Fukuta A, Shinahara W, Takahashi E, Yano M, Kido H: Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity. Vaccine 2011, 29:5368-5378.
• [33]Glasser SW, Senft AP, Whitsett JA, Maxfield MD, Ross GF, Richardson TR, Prows DR, Xu Y, Korfhagen TR: Macrophage dysfunction and susceptibility to pulmonary Pseudomonas aeruginosa infection in surfactant protein C-deficient mice. J Immunol 2008, 181:621-628.
• [34]Rudd BD, Burstein E, Duckett CS, Li X, Lukacs NW: Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol 2005, 79:3350-3357.
• [35]Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC, Hunninghake GW: Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 2006, 176:1733-1740.
• [36]Rudd BD, Smit JJ, Flavell RA, Alexopoulou L, Schaller MA, Gruber A, Berlin AA, Lukacs NW: Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol 2006, 176:1937-1942.